MADISON, Wis., Sept. 7, 2021 /PRNewswire/ — FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced management is scheduled to present at the Baird… read more →
– Data published in the Journal of Infectious Diseases demonstrate that M2SR can protect against a multi-seasonal, seven-year drifted influenza strain – MADISON, Wis., Aug. 2, 2021 /PRNewswire/ — FluGen, Inc., a… read more →
– Study is the Company’s first trial evaluating ability of M2SR and the current licensed standard of care to protect against drifted virus strains, and its second study in older… read more →
– Study will measure immune responses to matched and drifted virus strains in older adults, a population that is most vulnerable to mortality from flu – – Topline data expected… read more →